Saxendra’s revenue trends
In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.
In 2017, Saxendra generated revenues of 2.6 billion Danish kroner, which was a ~64% YoY growth in local currency.
In 2017 in the United States, Europe, and AAMEO (Asia, Africa, the Middle East, and Oceania), Saxendra generated revenues of 1.8 billion Danish kroner, 102 million Danish kroner, and 190 million Danish kroner, respectively. In the US market in 2017, Saxendra saw a ~36% YoY growth in local currency.
Novo Nordisk conducted a Phase 2 clinical trial with the semaglutide injection to evaluate the safety and efficacy of the drug for the treatment of individuals with obesity compared to a placebo and liraglutide. Novo Nordisk presented data at the Endocrine Society’s annual meeting in Chicago
In the Phase 2 clinical trial, after 52 weeks, obese individuals on once-daily semaglutide 0.4 mg (milligrams) subcutaneous injections demonstrated a weight loss up to 13.8% of their total body weight compared to 2.3% loss in body weight for patients receiving the placebo therapy.
In the obesity drugs market, Saxendra’s peers include Orexigen Therapeutics’ (OREXQ) Contrave, Eisai’s Belviq, Vivus’s (VVUS) Qsymia, and GlaxoSmithKline’s (GSK) Alli.
Growth disorder segment revenue trends
In 4Q17, Novo Nordisk’s growth disorder drugs segment generated revenues of 1.7 billion Danish kroner, which was a ~16% YoY decline.
In fiscal 2017, the segment saw a 22% YoY decline in local currencies and generated revenues of 6.7 billion Danish kroner. That included revenues of 2.5 billion Danish kroner, 1.6 billion Danish kroner, 676 billion Danish kroner, 1.6 billion Danish kroner, and 263 million Danish kroner in the United States, Europe, AAMEO, Japan and Korea, and Latin America, respectively.